Research programme: tumour suppressing gene therapies - Introgen

Drug Profile

Research programme: tumour suppressing gene therapies - Introgen

Alternative Names: INGN 402; INGN 403; Nanoparticle formulation mda-7; Nanoparticle formulation p53

Latest Information Update: 18 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Introgen Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; Interleukin 24 stimulants; P53 gene stimulants; Tumour suppressor gene transcription stimulants; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 04 Feb 2008 Preclinical development is ongoing for INGN 402 and INGN 403 in Solid tumours
  • 17 Jan 2007 Preclinical data added to the drug interactions section
  • 14 Dec 2006 Preclinical development still ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top